Product image of Iloprost Zentiva (Iloprost) supplied by GNH India

Iloprost Zentiva

Active Ingredient:
Iloprost
Origin:
EU

Iloprost Zentiva (Iloprost)

Iloprost, the active ingredient in Iloprost Zentiva, is a prostacyclin analog presented as a sterile intravenous solution for injection use. It is employed in the management of pulmonary arterial hypertension and in the treatment of digital ulcers associated with systemic sclerosis, targeting patients with these serious vascular conditions.

GNH India supplies Iloprost Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance throughout.

Manufacturer / TM Owner

Zentiva France

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Iloprost is a prostacyclin analog used in the management of pulmonary vascular disorders.
  • Pulmonary arterial hypertension: improves hemodynamics and exercise capacity in affected patients.
  • Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces pain.

How It Works

  • Iloprost mimics endogenous prostacyclin (PGI2) and selectively activates the IP (prostacyclin) receptor on vascular smooth‑muscle cells. Receptor activation increases intracellular cyclic AMP, leading to potent vasodilation of pulmonary and systemic arteries and inhibition of platelet aggregation, thereby reducing pulmonary vascular resistance and improving tissue perfusion.

Side Effects

Iloprost may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Flushing: transient warmth and redness of the skin.
  • Nausea or vomiting: gastrointestinal discomfort.
  • Hypotension: drop in blood pressure, especially with rapid infusion.
  • Jaw pain or toothache: often described as a dull ache.
  • Cough or throat irritation: related to the intravenous route.

Serious or Rare Side Effects

  • Pulmonary edema: accumulation of fluid in the lungs.
  • Severe hypotension: marked blood‑pressure decline requiring intervention.
  • Bleeding complications: due to platelet inhibition.
  • Arrhythmias: abnormal heart rhythms.
  • Thrombocytopenia: low platelet count.
  • Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity.

Precautions & Warnings

  • When using Iloprost, clinicians should observe several safety measures.
  • Monitor blood pressure: watch for hypotensive episodes during and after infusion.
  • Assess bleeding risk: avoid use in patients with active hemorrhage or uncontrolled coagulopathy.
  • Evaluate for pulmonary edema: discontinue if signs of fluid overload appear.
  • Use caution in recent myocardial infarction: cardiac stress may be increased.
  • Adjust in severe renal or hepatic impairment: consider reduced infusion rates.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Iloprost can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): increased risk of bleeding.
  • Other prostacyclin analogs (e.g., epoprostenol): additive vasodilatory effects leading to severe hypotension.
  • Endothelin receptor antagonists combined with high‑dose iloprost: may cause excessive pulmonary vasodilation.

Moderate Interactions (Monitor Closely)

  • Aspirin or NSAIDs: may enhance platelet inhibition.
  • Phosphodiesterase‑5 inhibitors (e.g., sildenafil): potential additive vasodilatory effect.
  • Beta‑blockers: may blunt compensatory heart‑rate response to hypotension.

Frequently Asked Questions

Iloprost Zentiva is indicated for the treatment of pulmonary arterial hypertension, a serious condition that raises pressure in the lungs' arteries, and for digital ulcers that develop in patients with systemic sclerosis, helping to improve blood flow and promote ulcer healing.

Iloprost mimics the natural prostacyclin molecule, binding to IP receptors on vascular smooth‑muscle cells. This activation raises cyclic AMP levels, causing the blood vessels to relax (vasodilation) and inhibiting platelet aggregation, which together lower pulmonary arterial pressure and improve tissue perfusion.

The specific dose and infusion schedule of Iloprost Zentiva are determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and tolerance. Dosing is individualized and should follow the prescriber’s instructions.

Safety data for Iloprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Iloprost belongs to the prostacyclin analog class, offering potent vasodilation and anti‑platelet effects. Compared with endothelin receptor antagonists or phosphodiesterase‑5 inhibitors, iloprost provides a direct prostacyclin pathway activation, which can be advantageous in patients who do not respond adequately to oral agents.

Iloprost Zentiva should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain stability.

Iloprost Zentiva is given as an intravenous infusion. The medication is diluted according to the prescribing information and administered over a set period, typically ranging from several minutes to a few hours, under medical supervision.

The most serious risks include severe hypotension, pulmonary edema, significant bleeding due to platelet inhibition, and rare anaphylactic reactions. Patients should be monitored closely for these events, especially during the initial infusion periods.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with active uncontrolled bleeding, and individuals who have experienced severe hypotension or pulmonary edema related to prostacyclin therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.